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118The Comprehensive Risk Assessment for Bypass
(CRAB) facilitates efﬁcient perioperative risk
assessment for patients with critical limb ischemia
Andrew J. Meltzer, MD,a Ashley Graham, BS,a Peter H. Connolly, MD,a Ellen C. Meltzer, MD,b
John K. Karwowski, MD,a Harry L. Bush, MD,a and Darren B. Schneider, MD,a New York, NY
Objective: Speciﬁc perioperative risk assessment models have been developed for bariatric, pancreatic, and colorectal
surgery. A similar instrument, speciﬁc for patients with critical limb ischemia (CLI), could improve patient-centered
clinical decision making. We describe a novel tool to predict 30-day major morbidity and mortality (M&M) after
bypass surgery for CLI.
Methods: Data for 4985 individuals from the 2007 to 2009 National Surgical Quality Improvement Program were used to
develop and internally validate the model. Outcome measures included mortality, major morbidity, and a composite end
point (M&M). M&M included mortality and the most severe postoperative morbidities that were highly associated with
death (eg, sepsis and major cardiopulmonary complications). More than 30 preoperative factors were tested for association
with 30-day mortality, major morbidity, and M&M. Signiﬁcant predictors in multivariate models were assigned integer
values (points), which were added to calculate a patient’s Comprehensive Risk Assessment For Bypass (CRAB) score.
Performance was assessed (C-index) across all outcome measures and compared with other general tools (American Society
of Anesthesiologists class, Surgical Risk Scale) and existing CLI-speciﬁc survival prediction models (Finnvasc score, Edi-
foligide for the Prevention of Infrainguinal Vein Graft Failure [PREVENT III] score) on a distinct validation sample (n[
1620).
Results: In the derivation data set (n [ 3275), the 30-day mortality rate was 2.9%. The rate of any major morbidity was
19.1%. The composite end point M&M occurred in 10.1%. Signiﬁcant predictors of M&M by multivariate analysis
included age >75 years, prior amputation or revascularization, tissue loss, dialysis dependence, severe cardiac disease,
emergency operation, and functional dependence. Applied to a distinct validation sample of 1620 patients, higher CRAB
scores were signiﬁcantly associated with higher rates of mortality, all major morbidities, and M&M (P < .0001).
Comparison with other models by assessment of area under the receiver-operating characteristic curve revealed the CRAB
was a more accurate predictor of mortality, all major morbidity, and M&M.
Conclusions: The CRAB is a CLI-speciﬁc, risk assessment instrument derived frommulti-institutional American College of
Surgeons-National Surgical Quality Improvement Program surgical outcomes data that out-performs existing prognostic
risk indices in the prediction of clinically signiﬁcant adverse events after bypass surgery.Use of theCRABas a risk assessment
tool provides an evidence basis for patient-centered clinical decision making and may have a role in identifying patients at
higher risk for surgical revascularization in whom an endovascular approach is preferable. (J Vasc Surg 2013;57:1186-95.)A diagnosis of critical limb ischemia (CLI) is associated
with signiﬁcant morbidity and mortality (M&M). One-year
major amputation and mortality rates are estimated at 35%
and 20%, respectively.1 The grim prognosis for patients
with CLI is attributable to the end-organ effects of a severe
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6associated conditions, including renal dysfunction, coro-
nary artery disease, and diabetes.
Surgical bypass with an autogenous saphenous venous
conduit is generally considered the gold standard treatment
to achieve limb preservation in patients with CLI.2,3
However, numerous recent reports describe acceptable
limb salvage rates with endovascular therapy in select
patients.4-6
Although the durability of endovascular interventions
in patients with CLI is inferior to bypass surgery, a mini-
mally invasive, endovascular approach may be preferable
in patients at the highest risk for perioperative adverse
events. Perioperative risk assessment is a fundamental
consideration for clinical decision making in CLI, but
patient suitability for surgery may be difﬁcult to determine.
Perioperative risk assessment is often focused on cardiac
risk stratiﬁcation and does not account for other common
causes of death and major morbidity.7-9 Existing general-
ized perioperative risk assessment tools, such as the Surgical
Risk Scale (SRS) or American Society of Anesthesiologists
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utility in the CLI population, where there is a much higher
prevalence of severe comorbidities.
Validated CLI-speciﬁc prognostic risk indices, such as
the modiﬁed Edifoligide for the Prevention of Infrainguinal
Vein Graft Failure (PREVENT III) Score, and the Bypass
vs Angioplasty in Severe Ischaemia of the Leg (BASIL)
survival prediction model, were developed to predict 1-
year amputation-free survival and 2-year overall survival,
respectively.10,11 Although long-term survival and limb
salvage are important considerations, patient selection for
surgical bypass vs endovascular therapy often hinges on
the ability of the patient to survive the procedure without
experiencing major morbidity. The immediate conse-
quences of the proposed intervention are a major practical
consideration for patients and vascular specialists, as evi-
denced by the existing body of research related to perioper-
ative risk assessment in this population.7-9,12
An additional limitation of existing risk prediction
instruments is their dependence on established outcome
measures such as survival, limb salvage, and amputation-
free survival. From a patient-centered perspective, the
importance of these end points for CLI remains unclear.
For example, one must consider the effect of postoperative
morbidity on health care-related quality of life and other
patient-centered outcomes and its role in shared decision
making.13,14
The objective of this study was to use multi-
institutional surgical outcomes data to derive a targeted
risk assessment instrument for CLI patients undergoing
bypass surgery. Here, we describe the development and
validation of the Comprehensive Risk Assessment for
Bypass (CRAB), a prognostic risk index that predicts the
likelihood of perioperative death or major morbidity, or
both, in patients undergoing surgical bypass for CLI.METHODS
Patient selection. The American College of Surgeons-
National Surgical Quality Improvement Program (ACS-
NSQIP) is a prospective, multicenter registry developed
primarily to provide feedback on risk-adjusted outcomes
to hospitals for quality-improvement purposes. Details
pertaining to data abstraction, sampling, and structure
of the participant use ﬁle (PUF) have been previously
reported.15-18 The ACS-NSQIP PUF consists of data
from >135 variables, including preoperative risk factors,
intraoperative variables, and 30-day postoperative M&M
outcomes for patients undergoing selected surgical proce-
dures. We identiﬁed patients undergoing infrainguinal
bypass surgery for CLI included in ACS-NSQIP PUFs from
2007 to 2009 by cross-referencing procedural and diag-
nostic codes. Patients undergoing infrainguinal reconstruc-
tion were identiﬁed by Current Procedural Terminology
(CPT; American Medical Association, Chicago, Ill) codes:
35556, 35566, 35570, 35571, 35583, 35585, 35587,
35656, 35666, and 35671. These codes account for
infrainguinal reconstruction with femoral or popliteal inﬂowto popliteal, tibial, or pedal targets, including reconstruction
performed with prosthetic conduit or autogenous vein.
To limit the data set to patients with CLI, patients were
only included if associated with appropriate International
Classiﬁcation of Diseases, 9th Revision (ICD-9) codes to
eliminate those undergoing bypass for claudication, arterial
reconstruction in the setting of another procedure (eg,
iatrogenic injury, tumor resection), or for other reasons.
Associated ICD-9 codes deemed appropriate for inclusion
were 440.22 (atherosclerosis with rest pain), 440.23 (ulcer-
ation), and 440.24 (gangrene). Although these diagnostic
codes were present in the majority of cases (92.6%),
patients undergoing surgical bypass with associated diag-
nostic codes representing pedal sepsis (681.1, 682.6,
682.7), lower extremity ulceration (707.1-707.19), or
unspeciﬁed gangrene (785.4) were also included.
Variables and outcome deﬁnitions. The study objec-
tive was the development of a clinical prediction model for
severe perioperative adverse events after surgical bypass for
CLI. All complications captured by ACS-NSQIP were
recoded by affected organ system and severity. Major
complications included organ system complications (eg,
acute renal failure, myocardial infarction or cardiopulmo-
nary resuscitation, prolonged or unplanned intubation,
pneumonia, venous thromboembolism, stroke, coma, and
nerve injury), systemic complications (eg, sepsis), and
technical considerations (eg, early graft failure and major
wound complications). Minor complications (eg, post-
operative urinary tract infection without sepsis) and
superﬁcial wound complications in the absence of severe
sequelae were not included in subsequent statistical
analyses.
We deﬁned three distinct outcome measures, including
perioperative (30-day) mortality, 30-day major morbidity,
as deﬁned above, and a composite end point of mortality
and major complications (M&M) most commonly associ-
ated with death. Therefore, M&M represents patients
who died in the postoperative period and survivors who
suffered severe postoperative complications highly associ-
ated with death, including sepsis and major organ system
dysfunction affecting the cardiac, pulmonary, renal, and
neurologic systems. In addition to the M&M outcome
measure, we recorded mortality alone, as well as “all major
morbidity,” which comprised all major complications,
including those not highly correlated with postoperative
death such as deep vein thrombosis and major wound
complications.
Demographic variables considered included age, sex,
race, smoking history, and alcohol use. Preoperative func-
tional status (independent, partially dependent, and totally
dependent) refers to the patient’s ability to perform activi-
ties of daily living preoperatively. Body mass index was
stratiﬁed into categories of normal weight, underweight,
overweight, and obese.
Concomitant medical conditions included diabetes,
severe chronic obstructive pulmonary disease (resulting in
functional disability, previous hospitalization, a forced
expiratory volume in 1 second of 75% of predicted, or
Table I. Patient demographics, comorbidities, and procedural details of the total sample, derivation, and validation data
sets
Covariate Total, No. (%) Derivation, No. (%) Validation, No. (%) P
Total 4894 (100) 3275 (100.0) 1619 (100)
Demographics
Female 1954 (39.9) 1256 (38.4) 698 (43.1) .0014
Male 2939 (60.1) 2018 (61.6) 921 (56.9)
Non-Caucasian 1370 (28.0) 946 (28.9) 424 (26.2) .048
Caucasian 3524 (72.0) 2329 (71.1) 1195 (73.8)
Age >75 years 1762 (36.0) 1145 (35.0) 617 (38.1) .034
Age <75 years 3132 (64.0) 2130 (65.0) 1002 (61.9)
Indication for surgery
Rest pain 1471 (30.1) 1007 (30.7) 464 (28.7) .1336
Ulcer gangrene 3423 (69.9) 2268 (69.3) 1155 (71.3)
Comorbidities
Body mass index
Normal 1762 (36.0) 1161 (35.5) 601 (37.1) .067
Underweight 235 (4.8) 144 (4.4) 91 (5.6)
Overweight 1518 (31.0) 1004 (30.7) 514 (31.7)
Obese 1233 (25.2) 859 (26.2) 374 (23.1)
Very obese 115 (2.3) 76 (2.3) 39 (2.4)
FHS
Independent 3725 (76.1) 2507 (76.5) 1218 (75.2) .151
Partial dependence 1071 (21.9) 711 (21.7) 360 (22.2)
Total dependence 98 (2.0) 57 (1.7) 41 (2.5)
Smoking (e) 1797 (36.7) 1223 (37.3) 574 (35.5) .197
Smoking (þ) 3097 (63.3) 2052 (62.7) 1045 (64.5)
Alcohol (e) 4628 (94.6) 3089 (94.3) 1539 (95.1) .2835
Alcohol (þ) 266 (5.4) 186 (5.7) 80 (4.9)
Diabetes (e) 2360 (48.2) 1568 (47.9) 792 (48.9) .493
Diabetes (þ) 2534 (51.8) 1707 (52.1) 827 (51.1)
Dyspnea (e) 3996 (81.7) 2682 (81.9) 1314 (81.2) .7749
Dyspnea on exertion 788 (16.1) 522 (15.9) 266 (16.4)
Dyspnea at rest 110 (2.2) 71 (2.2) 39 (2.4)
Prior revasc/amp (e) 2208 (45.1) 1473 (45) 735 (45.4) .773
Prior revasc/amp (þ) 2686 (54.9) 1802 (55) 884 (54.6)
Dialysis (e) 4409 (90.1) 2935 (89.6) 1474 (91)
Dialysis (þ) 485 (9.9) 340 (10.4) 145 (9)
Impaired sensorium (e) 4854 (99.2) 3251 (99.3) 1603 (99) .4424
Impaired sensorium (þ) 40 (0.8) 24 (0.7) 16 (1)
Wound/infection (e) 2090 (42.7) 1403 (42.8) 687 (42.4) .7913
Wound/infection (þ) 2804 (57.3) 1872 (57.2) 932 (57.6)
Steroid (e) 4661 (95.2) 3108 (94.9) 1553 (95.9) .1138
Steroid (þ) 233 (4.8) 167 (5.1) 66 (4.1)
Weight loss (e) 4797 (98.0) 3213 (98.1) 1584 (97.8) .527
Weight loss (þ) 97 (2.0) 62 (1.9) 35 (2.2)
Bleeding disorder (e) 3730 (76.2) 2495 (76.2) 1235 (76.3) .9203
Bleeding disorder (þ) 1164 (23.8) 780 (23.8) 384 (23.7)
Transfusion (e) 4886 (99.8) 3270 (99.8) 1616 (99.8) .725
Transfusion (þ) 8 (0.2) 5 (0.2) 3 (0.2)
Hx stroke/TIA (e) 4078 (83.3) 2745 (83.8) 1333 (82.3) .191
Hx stroke/TIA (þ) 816 (16.7) 530 (16.2) 286 (17.7)
COPD (e) 4263 (87.1) 2854 (87.1) 1409 (87) .92
COPD (þ) 631 (12.9) 421 (12.9) 210 (13)
Pneumonia (e) 4881 (99.7) 3264 (99.7) 1617 (99.9) .242
Pneumonia (þ) 13 (0.3) 11 (0.3) 2 (0.1)
CHF (e) 4730 (96.6) 3165 (96.6) 1565 (96.7) >.99
CHF (þ) 164 (3.4) 110 (3.4) 54 (3.3)
Prior PCI (e) 3993 (81.6) 2673 (81.6) 1320 (81.5) .9203
Prior PCI (þ) 901 (18.4) 602 (18.4) 299 (18.5)
Prior cardiac surgery (e) 3581 (73.2) 2394 (73.1) 1187 (73.3) .875
Prior cardiac surgery (þ) 1313 (26.8) 881 (26.9) 432 (26.7)
Angina/recent MI (e) 4673 (95.5) 3126 (95.5) 1547 (95.6) .8625
Angina/recent MI (þ) 221 (4.5) 149 (4.5) 72 (4.4)
Hypertension (e) 701 (14.3) 481 (14.7) 220 (13.6) .3009
Hypertension (þ) 4193 (85.7) 2794 (85.3) 1399 (86.4)
ASA 1 9 (0.2) 6 (0.2) 3 (0.2) .4825
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Table I. Continued.
Covariate Total, No. (%) Derivation, No. (%) Validation, No. (%) P
ASA 2 191 (3.9) 126 (3.8) 65 (4)
ASA 3 3497 (71.5) 2316 (70.7) 1181 (72.9)
ASA 4 1188 (24.3) 821 (25.1) 367 (22.7)
ASA 5 7 (0.1) 5 (0.2) 2 (0.1)
Procedural details
Inﬂow: femoral 4301 (87.9) 2869 (87.6) 1432 (88.4) .393
Inﬂow: popliteal/tibial 593 (12.1) 406 (12.4) 187 (11.6)
Outﬂow: popliteal 2376 (48.5) 1610 (49.2) 766 (47.3) .2238
Outﬂow: tibial/pedal 2518 (51.5) 1665 (50.8) 853 (52.7)
Conduit: vein 3507 (71.7) 2363 (72.2) 1144 (70.7) .275
Conduit: prosthetic 1387 (28.3) 912 (27.8) 475 (29.3)
Emergent (e) 4726 (96.6) 3163 (96.6) 1563 (96.5) >.99
Emergent (þ) 168 (3.4) 112 (3.4) 56 (3.5)
Amp, Amputation; ASA, American Society of Anesthesiologists Physical Status Classiﬁcation; CHF, congestive heart failure; COPD, chronic obstructive
pulmonary disease; FHS, Functional Health Status; Hx, history of; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient
ischemic attack.
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inhaled agents), congestive heart failure in the 30 days
before surgery, hypertension requiring medication, periph-
eral vascular disease requiring prior revascularization or
amputation, altered mental status or impaired sensorium,
regular steroid use in the 30 days before surgery, history
of bleeding disorders, end-stage renal disease necessitating
hemodialysis, prior percutaneous coronary intervention,
prior cardiac surgery, angina #1 preceding surgery or
myocardial infarction #6 months preceding surgery, prior
stroke, presence of wound or infection, and case urgency,
listed as emergent or nonemergent, as deﬁned by the oper-
ating surgeon.
Statistical analysis. Categoric variables in the training
and validation samples were compared using Pearson c2
tests. Distributions of continuous variables in the training
and validation samples were compared using Wilcoxon
rank-sum tests. We used 31 a priori selected preoperative
covariates from the model derivation data set to create
a multivariable logistic regression model. Variables were
considered for inclusion in the model if there was a signiﬁ-
cant trend toward association with mortality (P < .10) by
univariate analysis. To prevent model overﬁtting, variables
were tested for multicolinearity before inclusion in the
multivariable models, and ﬁnal decisions with respect to co-
variate inclusion in multivariable models were made based
on statistical signiﬁcance, clinical relevance, and ease of
assessment. Multivariable models were tested for signiﬁ-
cance and goodness of ﬁt. Variables included in the ﬁnal
model were assigned a component score based on the rela-
tive magnitude of the b coefﬁcients for each predictor vari-
able in the ﬁnal regression equation.
The CRAB for any given patient was derived by adding
the patient’s component scores and validated using the
distinct validation sample. The C-statistic, an estimate of
the area under the receiver-operating characteristic
(ROC) curve, was used to evaluate the discrimination of
our targeted risk prediction score for the outcomemeasures of mortality, major morbidity, and M&M. The
respective model ﬁt for the ASA score, the Surgical Risk
Scale, Finnvasc score, and the PREVENT III clinical
prediction model was also evaluated by calculating the
respective score for each of these prediction models in all
patients included in the validation sample.
RESULTS
We identiﬁed 4895 patients for whom perioperative
data were captured and included in the ACS-NSQIP
PUF for calendar years 2007, 2008, and 2009, who under-
went infrainguinal bypass surgery for CLI. Patient records
were assigned to a distinct model derivation (training)
data set (2/3) or a model validation data set (1/3).
Table I summarizes the demographic characteristics, prev-
alence of comorbidities, and treatment details, such as
conduit choice, inﬂow level, and distal target for all
patients, as well as the distinct training and validation
sets. Overall, 60.1% of patients were men, 72.0% were
Caucasian, and 56.1% were aged <75 years. Surgery in
69.9% of patients was for tissue loss and for rest pain
without ulceration or gangrene in the rest.
Highly prevalent comorbidities include hypertension
requiring medical therapy (85.7%), diabetes (51.8%),
partial or total functional dependence (23.9%), hemodial-
ysis dependence (9.9%), and previous cardiac surgery
(26.8%). Most patients (54.9%) had undergone amputation
or revascularization for PAD. The inﬂow source was the
femoral artery in 87.9% of patients; tibial or pedal targets
(51.5%) were more common than popliteal artery distal
target (48.5%). Prosthetic conduit was used in 28.3%.
The overall mortality rate was 2.9%. The rate of major
morbidity was 19.1%, including systemic complications
(eg, sepsis), major wound complications, organ dysfunction
(eg, cardiac, pulmonary, renal, or neurologic complications),
and graft failure. Major postoperative morbidities most
frequently associated with death, and included in the
M&M composite variable, included sepsis, which preceded
Table II. Univariate analysis: Predictors of mortality and major morbidity in the derivation data set
Covariate No. Mortality, No. (%) P Major morbidity, No. (%) P
Total 3275 94 (2.9) NA 623 (19) NA
Demographics
Female 1256 47 (3.7) .06 255 (20.3) .304
Male 2018 47 (2.3) 368 (18.2)
Non-Caucasian 946 34 (3.6) .114 184 (19.5) .691
Caucasian 2329 60 (2.6) 439 (18.8)
Age >75 years 1145 50 (4.4) <.0001 234 (20.3) .131
Age <75 years 2130 44 (2.1) 389 (18.3)
Indication
Rest pain 1007 11 (1.1) <.0001 150 (14.9) <.0001
Ulcer gangrene 2268 83 (3.7) 473 (20.9)
Comorbidities
Body mass index
Normal 1161 35 (3) .864 194 (16.7) .001
Underweight 144 5 (3.5) 19 (13.2)
Overweight 1004 31 (3) 192 (18.6)
Obese 859 22 (2.6) 202 (23.5)
Very obese 76 1 (1.3) 16 (21.1)
FHS
Independent 2507 54 (2.2) <.0001 409 (16.3) <.0001
Partial dependence 711 34 (4.8) 196 (27.6)
Total dependence 57 6 (10.5) 18 (31.6)
Smoking (e) 1223 21 (1.7) .002 206 (16.8) .014
Smoking (þ) 2052 73 (3.6) 417 (20.3)
Alcohol (e) 3089 90 (2.9) .545 589 (19.1) .79
Alcohol (þ) 186 4 (2.2) 34 (18.3)
Diabetes (e) 1568 40 (2.6) .294 283 (18) .173
Diabetes (þ) 1707 54 (3.2) 340 (19.9)
Dyspnea (e) 2682 64 (2.4) <.0001 497 (18.5) .312
Dyspnea on exertion 522 22 (4.2) 111 (21.3)
Dyspnea at rest 71 8 (11.3) 15 (21.1)
Prior revasc/amp (e) 1473 34 (2.3) .082 239 (16.2) <.0001
Prior revasc/amp (þ) 1802 60 (3.3) 384 (21.3)
Dialysis (e) 2935 66 (2.2) <.0001 531 (18.1) <.0001
Dialysis (þ) 340 28 (8.2) 92 (27.1)
Impaired sensorium (e) 3251 92 (2.8) .108 620 (19.1) .414
Impaired sensorium (þ) 24 2 (8.3) 3 (12.5)
Wound/infection (e) 1403 32 (2.3) .08 229 (16.3) .001
Wound/infection (þ) 1872 62 (3.3) 394 (21)
Steroid (e) 3108 84 (2.7) .013 581 (18.7) .038
Steroid (þ) 167 10 (6) 42 (25.1)
Weight loss (e) 3213 94 (2.9) .172 615 (19.1) .215
Weight loss (þ) 62 0 (0) 8 (12.9)
Bleeding disorder (e) 2495 64 (2.6) .061 451 (18.1) .014
Bleeding disorder (þ) 780 30 (3.8) 172 (22.1)
Transfusion (e) 3270 94 (2.9) .7 621 (19) .232
Transfusion (þ) 5 0 (0) 2 (40)
Hx stroke/TIA (e) 2745 73 (2.7) .1 506 (18.4) .05
Hx stroke/TIA (þ) 530 21 (4) 117 (22.1)
COPD (e) 2854 73 (2.6) .005 530 (18.6) .086
COPD (þ) 421 21 (5) 93 (22.1)
Pneumonia (e) 3264 93 (2.8) .216 618 (18.9) .025
Pneumonia (þ) 11 1 (9.1) 5 (45.5)
CHF (e) 3165 84 (2.7) <.0001 599 (18.9) .447
CHF (þ) 110 10 (9.1) 24 (21.8)
Prior PCI (e) 2673 73 (2.7) .315 486 (18.2) .01
Prior PCI (þ) 602 21 (3.5) 137 (22.8)
Prior cardiac surgery (e) 2394 58 (2.4) .011 434 (18.1) .032
Prior cardiac surgery (þ) 881 36 (4.1) 189 (21.5)
Angina/recent MI (e) 3126 85 (2.7) .018 578 (18.5) <.0001
Angina/recent MI (þ) 149 9 (6) 45 (30.2)
Hypertension (e) 481 12 (2.5) .593 72 (15) .014
Hypertension (þ) 2794 82 (2.9) 551 (19.7)
ASA 1 6 0 (0) .002 1 (16.7) <.0001
ASA 2 126 1 (0.8) 12 (9.5)
JOURNAL OF VASCULAR SURGERY
1190 Meltzer et al May 2013
Table II. Continued.
Covariate No. Mortality, No. (%) P Major morbidity, No. (%) P
ASA 3 2316 51 (2.2) 400 (17.3)
ASA 4 821 42 (5.1) 208 (25.3)
ASA 5 5 0 (0) 5 (20)
Procedural details
Inﬂow: femoral 2869 81 (2.8) .669 538 (18.8) .294
Inﬂow: popliteal/tibial 406 13 (3.2) 85 (20.9)
Outﬂow: popliteal 1610 49 (3) .559 277 (17.2) .009
Outﬂow: tibial/pedal 1665 45 (2.7) 346 (20.8)
Conduit: vein 2363 67 (2.8) .848 456 (19.3) .519
Conduit: prosthetic 912 27 (3) 167 (18.3)
Emergent (þ) 112 87 (2.8) .029 588 (18.6) .001
Emergent (e) 3163 7 (6.3) 35 (31.3)
Amp, Amputation; ASA, American Society of Anesthesiologists Physical Status Classiﬁcation; CHF, congestive heart failure; COPD, chronic obstructive
pulmonary disease; FHS, Functional Health Status; Hx, history of; MI, myocardial infarction; NA, not applicable; CI, percutaneous coronary intervention;
TIA, transient ischemic attack.
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occurred in 44% of deaths, and major pulmonary complica-
tions, which occurred in 37.5% of deaths. Themortality rates
for patients with these complications were 19%, 33%, and
42%, respectively. The overall M&M rate was 10.1%.
The prevalence of comorbidities among those patients
who died or suffered major morbidity are summarized in
Table II; the prevalence of comorbidities in the derivation
data set and their individual association with M&M by
univariate analysis are reported in Table III. Statistically
signiﬁcant predictors of M&M by univariate analysis
included age >75, tissue loss (vs rest pain), partial or total
function dependence, smoking history, diabetes, prior
extremity revascularization or amputation, dialysis depen-
dence, open wound or infection, bleeding disorder,
chronic obstructive pulmonary disease, pneumonia,
congestive heart failure, prior percutaneous coronary inter-
vention or cardiac surgery, angina #1 month before
surgery, or myocardial infarction #6 months, and emer-
gent case status.
Multivariate regression (odds ratio [95% conﬁdence
interval]) identiﬁed independent predictors of M&M as
age >75 years (1.385 [1.088-1.7464]; P ¼ .008), prior
amputation or revascularization (1.425 [1.121-1.812];
P¼ .004), tissue loss (1.477 [1.1-1.983]; P¼ .009), hemo-
dialysis (2.083 [1.526-2.842]; P < .0001), severe cardiac
disease (2.26 [1.484-3.44]; P < .0001), and emergent
surgery (2.86 [1.798-4.549]; P < .0001). Also predictive
of adverse events were partial functional dependence
(1.675 [1.291-2.174]; P < .0001) and total functional
dependence (3.233 [1.731-6.039]); P < .0001). These
covariates were assigned an integer score (Table IV) based
on the magnitude of their contribution to adverse events
in multivariate models. Summing the integer component
scores for any given patient allows for calculation of the
CRAB score.
Applied to the validation data set, the rates of mortality,
M&M, and major morbidity all increased with increasing
CRAB score (P < .0001 for all comparisons). Althoughthe CRAB score may range from 0 to 29 and should be
viewed as a continuously measured end point through this
range, the occurrence of the mortality and composite
M&M end points in the validation data set are graphically
represented across three risk strata. In the validation sample,
M&M occurred in 6% of those at lowest risk for adverse
events (CRAB 0-6) compared with 13.4% for those at
moderate risk (CRAB 7-12) and 25% for those at highest
risk for complications (CRAB >12). Mortality ranged
from 1.1% among those at lowest rick to 11.4% among those
at highest risk by the CRAB model. The CRAB also pre-
dicted all major morbidities (Table V and Fig).
Compared with other existing generalized and CLI-
speciﬁc models on the validation data set, the CRAB
offered better discrimination of the likelihood of mortality
(C-index: 0.77; P < .0001), M&M (0.68; P < .0001), and
major morbidity (0.61; P < .0001) than other models
(Table VI).DISCUSSION
Surgical bypass using an autogenous saphenous vein
conduit has historically been considered the gold standard
treatment to achieve limb preservation in patients with
CLI.2,3 Numerous recent reports, however, have identiﬁed
a role for endovascular therapy in selected patients with
limb-threatening ischemia.4-6 Although the availability of
these complimentary approaches may beneﬁt patients and
providers alike, identiﬁcation of the optimal revasculariza-
tion strategy for any given patient can be challenging.
The heralded BASIL trial remains the only randomized,
controlled study addressing this issue,19 but debate
surrounding the applicability of BASIL with respect to
disease severity and treatment modalities highlights an
inherent limitation of randomized controlled trials:
however well-designed, the trial results may not be readily
applicable to the individual patients encountered in clinical
practice. Furthermore, cost considerations and concerns
regarding clinical equipoise will likely prohibit randomized
Table III. Univariate analysis: predictors of themorbidity
and mortality (M&M) composite end point
Covariate No. M&M, No. (%) P
Total 3275 334 (10.2) NA
Demographics
Female 1256 143 (11.4) .199
Male 2018 191 (9.5)
Non-Caucasian 946 96 (10.1) .951
Caucasian 2329 238 (10.2)
Age >75 years 1145 139 (12.1) .007
Age <75 years 2130 195 (9.2)
Indication
Rest pain 1007 66 (6.6) .0001
Ulcer gangrene 2268 268 (11.8)
Comorbidities
Normal weight 1161 108 (9.3) .351
Underweight 144 11 (7.6)
Overweight 1004 107 (10.3)
Obese 859 101 (11.8)
Very obese 76 7 (9.2)
FHS
Independent 2507 202 (8.1) .0001
Partial dependence 711 116 (16.3)
Total dependence 57 16 (28.1)
Smoking (e) 1223 100 (8.2) .003
Smoking (þ) 2052 234 (11.4)
Alcohol (e) 3089 320 (10.4) .215
Alcohol (þ) 186 14 (7.5)
Diabetes (e) 1568 142 (9.1) .038
Diabetes (þ) 1707 192 (11.2)
Dyspnea (e) 2682 256 (9.5) .017
Dyspnea on exertion 522 66 (12.6)
Dyspnea at rest 71 12 (16.9)
Prior revasc/amp (e) 1473 127 (8.6) .007
Prior revasc/amp (þ) 1802 207 (11.5)
Dialysis (e) 2935 267 (9.1) .0001
Dialysis (þ) 340 67 (19.7)
Impaired sensorium (e) 3251 330 (10.2) .293
Impaired sensorium (þ) 24 4 (16.7)
Wound/infection (e) 1403 110 (7.8) .0001
Wound/infection (þ) 1872 224 (12)
Steroid (e) 3108 308 (9.9) .019
Steroid (þ) 167 26 (15.6)
Weight loss (e) 3213 330 (10.3) .325
Weight loss (þ) 62 4 (6.5)
Bleeding disorder (e) 2495 238 (9.5) .026
Bleeding disorder (þ) 780 96 (12.3)
Transfusion (e) 3270 334 (10.2) .451
Transfusion (þ) 5 0 (0)
Hx stroke/TIA (e) 2745 262 (9.5) .005
Hx stroke/TIA (þ) 530 72 (13.6)
COPD (e) 2854 264 (9.3) .0001
COPD (þ) 421 70 (16.6)
Pneumonia (e) 3264 330 (10.1) .004
Pneumonia (þ) 11 4 (36.4)
CHF (e) 3165 315 (10) .013
CHF (þ) 110 19 (17.3)
Prior PCI (e) 2673 256 (9.6) .013
Prior PCI (þ) 602 78 (13)
Prior cardiac surgery (e) 2394 226 (9.4) .018
Prior cardiac surgery (þ) 881 108 (12.3)
Angina /recent MI (e) 3126 301 (9.6) .0001
Angina/recent MI (þ) 149 33 (22.1)
Hypertension (e) 481 36 (7.5) .033
Hypertension (þ) 2794 298 (10.7)
ASA 1 6 0 (0) .0001
ASA 2 126 3 (2.4)
Table III. Continued.
Covariate No. M&M, No. (%) P
ASA 3 2316 189 (8.2)
ASA 4 821 142 (17.3)
ASA 5 5 0 (0)
Procedural details
Inﬂow: femoral 2869 289 (10.1) .529
Inﬂow: popliteal/tibial 406 45 (11.1)
Outﬂow: popliteal 1610 155 (9.6) .288
Outﬂow: tibial/pedal 1665 179 (10.8)
Conduit: vein 2363 247 (10.5) .439
Conduit: prosthetic 912 87 (9.5)
Emergent (þ) 112 306 (9.7) .0001
Emergent (e) 3163 28 (25)
Amp, Amputation; ASA, American Society of Anesthesiologists Physical
Status Classiﬁcation; CHF, congestive heart failure; COPD, chronic
obstructive pulmonary disease; FHS, Functional Health Status; Hx, history
of; MI, myocardial infarction; NA, not applicable; PCI, percutaneous
coronary intervention; TIA, transient ischemic attack.
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therapeutic approach at the patient-speciﬁc level.
Recently, investigators have used multi-institutional
surgical outcomes data, such as that available from the
NSQIP to construct speciﬁc clinical prediction models for
mortality or major morbidity, or both, after colorectal,
bariatric, and pancreatic surgery.16-20 Theoretically, such
targeted models may allow for outcome prediction based
on a limited number of variables and may be used to inform
clinical decision making at the patient-speciﬁc level.
Here, we present the ﬁrst NSQIP-based prognostic risk
index for perioperative adverse events speciﬁc to patients
undergoing surgical bypass for CLI. By multivariate anal-
ysis, the factors independently associated with adverse peri-
operative outcomes were advanced age (>75 years),
a history of peripheral vascular disease, including prior
amputation or attempt at revascularization, the presence
of tissue loss (vs rest pain), hemodialysis dependence,
recent angina or myocardial infarction, emergency surgery,
and dependent functional status. These risk factors, which
can be easily ascertained by cursory patient evaluation or
record review, are assigned component scores of 3, 4, or
6 points, with these relative weights based on their indi-
vidual contribution to perioperative M&M.
Addition of the component scores for any given patient
yields the overall CRAB score. The scoring system was
applied to a distinct validation sample, and outcomes varied
dramatically by CRAB score in a distinct validation data set
(Fig). Patients with CRAB scores <6 had a 1.1% mortality
rate, whereas those with scores >12 had a mortality rate of
11.4%. The overall major morbidity rate increased with
increasing CRAB score, as did the perioperative M&M
composite, which increased from 6% to 24.6% in low-risk
and high-risk patients, respectively.
Previous efforts to predict outcome in this speciﬁc patient
population include the BASIL survival prediction model,
modiﬁed PREVENT III score, and Finnvasc score.10-12
The BASIL model predicts overall survival at 2 years. The
modiﬁed PREVENT III score was designed to predict
Table IV. Multivariate analysis: Risk factors formorbidity
and mortality (M&M) with component scores
Covariate Points OR (95% CI) P
Age >75 years 3 1.385 (1.088-1.7464) .008
Prior amputation
/revascularization
3 1.425 (1.121-1.812) .004
Ulceration (vs rest pain) 3 1.477 (1.1-1.983) .009
Partial functional
dependence
3 1.675 (1.291-2.174) <.0001
Hemodialysis 4 2.083 (1.526-2.842) <.0001
Recent angina/MI 4 2.26 (1.484-3.44) <.0001
Emergent case 6 2.86 (1.798-4.549) <.0001
Total functional
dependence
6 3.233 (1.731-6.039) <.0001
CI, Conﬁdence interval; MI, myocardial infarction; OR, odds ratio.
Table V. Mortality, morbidity and mortality (M&M),
and major morbidity rates by Comprehensive Risk
Assessment for Bypass (CRAB) score in the distinct
validation sample
Score N
Mortality,
No. (%)
M&M,
No. (%)
Morbidity,
No. (%)
Overall 1619 50 (3.1) 154 (9.5) 298 (18.4)
Low (0-6) 1019 11 (1.1) 61 (6) 164 (16.4)
Medium (7-12) 486 26 (5.3) 65 (13.4) 94 (19.3)
High (>12) 114 13 (11.4) 28 (24.6) 37 (32.5)
Fig. Variation in complication rates by Comprehensive Risk
Assessment for Bypass (CRAB) score suggests patients at the
highest risk for complications.
Table VI. Comparison of C-statistics for American
Society of Anesthesiologists (ASA), Surgical Risk Scale
(SRS), modiﬁed PREVENT III (PIII) score, Finnvasc
Score, and Comprehensive Risk Assessment for Bypass
(CRAB) with respect to mortality and morbidity and
mortality (M&M) as applied to the validation data set
Variable
Area under the curve
Derivation data Validation data
Mortality
ASA 0.607 0.635
SRS 0.622 0.64
Finnvasc 0.598 0.632
PIII 0.66 0.685
CRAB 0.737 0.765
M&M
ASA 0.605 0.568
SRS 0.625 0.564
Finnvasc 0.587 0.58
PIII 0.608 0.617
CRAB 0.682 0.675
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and limb salvage are important considerations to identify
patients who may beneﬁt most from surgical bypass, patient
selection for surgical bypass (vs endovascular therapy) also
warrants consideration of the likelihood of perioperative
adverse events. The immediate consequences of a proposed
intervention are a practical consideration for patients and
vascular specialists and ﬁgures prominently in surgical deci-
sion making. Although the Finnvasc scoring system was
developed to predict amputation-free survival at 30 days, it
has proven only modestly predictive of this outcome.12
Furthermore, existing prognostic risk indices do not evaluate
the potential for major morbidity associated with bypass
surgery in CLI, despite the observable impact of postopera-
tive morbidity on health-related quality of life and patient-
centered outcomes.13,14
Interestingly, there is overlap between the various scor-
ing methods, despite variation in methodologies and the tar-
geted outcome. Independent predictors of amputation-free
survival in the PREVENT III cohort included renal insufﬁ-
ciency, tissue loss, advanced age, anemia, and coronary artery
disease. In the Finnvasc registry, coronary disease, diabetes,
gangrene, and emergency surgery were independent pre-
dictors of 30-day amputation-free survival.11 Many of these
variables, including advanced age, renal insufﬁciency, tissue
loss, emergency surgery, and coronary disease, are also
included in the CRAB.10 The BASIL-derived prediction
model includes age, history of myocardial infarction orangina, presence of tissue loss, history of stroke or transient
ischemic attack, and serum creatinine, in addition to ankle
pressure measurements and angiographic scoring.12 The
similarities among the various models conﬁrm prior reports
and the aggregate clinical wisdom, all of which suggests
that advanced age, severe diseasewith tissue loss, renal failure,
and poor coronary status portend poor outcome.10-13,21,22
The value of predictive models, such as the BASIL
survival score, PREVENT III score, Finnvasc score, and
the CRAB, is their ability to quantify the relative effect of
these risk factors on the outcome of interest. The CRAB
is an important addition and may be even more applicable
to current clinical practice than the existing predictive
models for several reasons. The NSQIP database consists
of real-world patients who underwent surgical bypass using
a variety of techniques, inﬂow and outﬂow vessels, and
conduits. Moreover, this contemporary multi-institutional
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sion criteria for a clinical trial.
We strongly believe that perioperative outcome ﬁgures
prominently in clinical decision making in CLI. Whereas
other models succeed in predicting long-term success of
interventions, the value of the CRAB is its role in perioper-
ative risk assessment. Beyond simply cardiac risk stratiﬁca-
tion, the CRAB offers good prediction of all-cause
mortality and major morbidity after surgery. With respect
to this composite end point, the CRAB out-performed
the ASA classiﬁcation, the Surgical Risk Scale, PREVENT
III score, and Finnvasc score, as evidenced by superior esti-
mated areas under the ROC curves.
Limitations of the CRAB include its retrospective
nature and the inherent difﬁculties associated with the
NSQIP coding and data collection processes.16-20 It is
also important to note that, despite the overlap between
covariates included in the CRAB and other instruments,
the CRAB is the only tool speciﬁcally designed to predict
perioperative M&M. Therefore, one would expect the
current model to out-perform instruments designed for
prediction of a different targeted outcome, and compari-
sons with existing models by ROC curve analysis must be
considered in this light.
In addition, the CRAB data were derived from
patients who underwent surgery and presumably were
deemed “suitable” for operation. Therefore, those
patients who were determined unﬁt for bypass surgery
are absent from the analysis. We do not believe this dimin-
ishes the utility of the CRAB as an instrument to guide
surgical decision making because it is only those patients
who might actually tolerate surgery that pose a dilemma.
Patients who are obviously unﬁt—for whom bypass
surgery would not be considered by conventional assess-
ment—pose no difﬁculties from a decision-making stand-
point. Furthermore, given the increasing popularity of an
endovascular-ﬁrst approach, it is probable that many
patients included in the analysis represent those in
whom endovascular therapy was unsuccessful. This would
obviously affect the utility of this risk assessment tool with
respect to treatment selection.
Future efforts include prospective validation on a dis-
tinct data set to evaluate the accuracy of this instrument
in the prediction of adverse events after surgical revascular-
ization and also after endovascular revascularization, as well
as efforts to identify the utility of the CRAB in predicting
patient-centered outcomes such as independent living,
reinterventions, and ambulation.
CONCLUSIONS
The NSQIP-based CRAB is an efﬁcient, simple, and
accurate instrument that allows CLI-speciﬁc prediction of
adverse perioperative outcomes after surgical revasculariza-
tion based on readily identiﬁable preoperative characteris-
tics. The ability of this prognostic risk index to identify
patients at the greatest likelihood for adverse events
suggests a role for the CRAB in facilitating patient-
centered clinical decision making and in facilitatingevidence-based, individualized discussion of surgical risk
during the informed consent process.
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Submitted Aug 7, 2012; accepted Sep 25, 2012.INVITED COMMENTARYThomas S. Huber, MD, PhD, Gainesville, FlaThe authors have developed a risk assessment tool to predict
perioperative morbidity and mortality after infrainguinal bypass
in patients with critical limb ischemia using the National Surgical
Quality Improvement Program database. They reported an overall
mortality rate of 2.9% with a major morbidity rate of 19%. Not
surprisingly, they identiﬁed advanced age, prior revasculariza-
tion/amputation, tissue loss, dialysis dependence, severe cardiac
disease, emergent operation, and functional dependence as predic-
tors of adverse outcome. The sum of the weighted values assigned
to these predictors correlated well with the adverse outcomes in
their internal validation and the model itself compared favorably
with others reported in the literature. Despite the quality of the
study and the importance of predicting perioperative outcome, it
is not clear how the model should be used in clinical practice. Crit-
ical limb ischemia is a difﬁcult problem with poor long-term
outcomes in terms of wound healing, ambulation, limb salvage,
functional independence, and survival. The model deﬁnes perio-
perative outcome in a select group of patients presumably deemed
adequate risk to undergo open revascularization. Unfortunately, itfails to model any of these other important outcome measures that
may be far more relevant from a patient perspective. It is not clear
that the data can be used to support an endovascular approach as
an alternative to open revascularization as suggested by the
authors. With the widespread proliferation of the endovascular
therapies, most providers (ie, vascular surgeons, interventional
radiologists, cardiologists) have adopted an “endovascular ﬁrst”
approach and presumably many of the patients in the current study
would not have been endovascular candidates based upon their
distribution of occlusive disease and/or extent of tissue loss.
Notably, 70% of the patients in the current study had tissue loss,
and 55% had undergone a previous revascularization or amputa-
tion. Furthermore, it is conceivable that “medical management”
with local wound care or major amputation may be a better treat-
ment option in the highest-risk cohort of patients with critical limb
ischemia. I commend the authors for their excellent contribution
and look forward to their planned, future studies detailing perio-
perative and longer-term outcomes after the other treatment
options in this difﬁcult patient population.
